Avecho Biotechnology (ASX:AVE) Long-Term Capital Lease Obligation : A$0.01 Mil (As of Dec. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Avecho Biotechnology Long-Term Capital Lease Obligation?

Avecho Biotechnology's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$0.01 Mil.

Avecho Biotechnology's quarterly Long-Term Capital Lease Obligation declined from Dec. 2023 (A$0.10 Mil) to Jun. 2024 (A$0.00 Mil) but then increased from Jun. 2024 (A$0.00 Mil) to Dec. 2024 (A$0.01 Mil).

Avecho Biotechnology's annual Long-Term Capital Lease Obligation declined from Dec. 2022 (A$0.18 Mil) to Dec. 2023 (A$0.10 Mil) and declined from Dec. 2023 (A$0.10 Mil) to Dec. 2024 (A$0.01 Mil).

Avecho Biotechnology Long-Term Capital Lease Obligation Historical Data

The historical data trend for Avecho Biotechnology's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology Long-Term Capital Lease Obligation Chart

Avecho Biotechnology Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.09

0.01

0.18

0.10

0.01

Avecho Biotechnology Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.18	-	0.10	-	0.01

Avecho Biotechnology (ASX:AVE) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Avecho Biotechnology Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Avecho Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (ASX:AVE) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

OEZ:Germany

Address

Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168

Website

https://www.avecho.com.au

Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology Headlines

No Headlines